# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Needham analyst Gil Blum reiterates Generation Bio (NASDAQ:GBIO) with a Buy and maintains $15 price target.
Wedbush analyst David Nierengarten downgrades Generation Bio (NASDAQ:GBIO) from Outperform to Neutral and maintains the pric...
Shares of Sapiens International Corporation NV (NASDAQ:SPNS) rose sharply in pre-market trading after it announced on Wednesday...
Generation Bio (NASDAQ:GBIO) reported quarterly losses of $(3.12) per share which missed the analyst consensus estimate of $(2....